Sarepta Therapeutics (SRPT) Posts Smaller Q2 Loss on Higher Revenues

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. LMT
8. USO
9. META
10. TLT

Go back to Sarepta Therapeutics (SRPT) Posts Smaller Q2 Loss on Higher Revenues

Sarepta Therapeutics Announces Second Quarter 2018 Financial Results and Recent Corporate Developments

August 8, 2018 4:02 PM EDT

CAMBRIDGE, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, today reported financial results for the second quarter of 2018.

We are very pleased to report another strong quarter, marrying our vision to become one of the most meaningful precision genetic medicine companies globally with a strong focus on execution against both our near- and long-term range goals, stated Doug Ingram, Sareptas president and chief executive officer. Our robust quarterly sales for EXONDYS 51,... More